Department of General, Visceral, and Transplantation Surgery, Im Neuenheimer Feld 110, 69120 Heidelberg, Germany.
Nat Rev Clin Oncol. 2013 Jun;10(6):323-33. doi: 10.1038/nrclinonc.2013.66. Epub 2013 Apr 30.
Pancreatic ductal adenocarcinoma is one of the most aggressive cancers, and surgical resection is a requirement for a potential cure. However, the majority of patients are diagnosed with advanced-stage disease, either metastatic (50%) or locally advanced cancer (30%). Although palliative chemotherapy is the standard of care for patients with metastatic disease, management of locally advanced adenocarcinoma is controversial. Several treatment options, including extended surgical resections, neoadjuvant therapy with subsequent resections, as well as palliative radiotherapy and/or chemotherapy, should be considered. However, there is little evidence available to support treatment options for locally advanced disease. As valid predictive biomarkers for stratification of therapy are not available today, future trials need to define the role of the different treatment options. This Review summarizes the current evidence and discusses available treatment options for both locally advanced and metastatic pancreatic adenocarcinoma.
胰腺导管腺癌是最具侵袭性的癌症之一,手术切除是潜在治愈的必要条件。然而,大多数患者被诊断为晚期疾病,转移性(50%)或局部晚期癌症(30%)。虽然姑息化疗是转移性疾病患者的标准治疗方法,但局部晚期腺癌的治疗存在争议。几种治疗选择,包括扩大的手术切除、新辅助治疗后再切除,以及姑息性放疗和/或化疗,都应考虑。然而,目前几乎没有证据支持局部晚期疾病的治疗选择。由于目前没有有效的预测性生物标志物来分层治疗,因此未来的试验需要确定不同治疗选择的作用。本综述总结了目前的证据,并讨论了局部晚期和转移性胰腺腺癌的现有治疗选择。